Wow! A close friend of mine was told by the hospt that her baby had a very high chance of being born with Downs. She and her partner where obviously shocked and upset and researched throughly and planned accordingly to a future life with a child with Downs and decided to go ahead with the pregnancy regardless. The baby was born perfectly healthy and with no signs of having Downs. How on Earth can the medical field put a couple through that?! Imagine if they chose to abort! I have no words. π€¦π»ββοΈ
I refuse to shop at any store selling womenβs cloths that wonβt protect the female changing rooms as stated by Uk law. If we use the pound in our pocket shops will stop allowing a minority of loud voices to dictate unlawful policy putting girls & women in potential harms way.
Retatrutide (LY-3437943) is an investigational, once-weekly injectable medication developed by Eli Lilly for the treatment of obesity, type 2 diabetes, and related metabolic conditions.1
It is a triple hormone receptor agonist β the first of its kind β that simultaneously activates three key receptors:
β’GLP-1 (Glucagon-like peptide-1) receptor β Reduces appetite, slows gastric emptying, and improves insulin secretion.
β’GIP (Glucose-dependent insulinotropic polypeptide) receptor β Enhances insulin release and may improve fat metabolism (Retatrutide is particularly potent here).
β’Glucagon (GCG) receptor β Increases energy expenditure and fat burning, which helps explain its strong weight-loss effects.0
This triple action distinguishes it from:
β’Semaglutide (Ozempic/Wegovy) β GLP-1 only.
β’Tirzepatide (Mounjaro/Zepbound) β Dual GIP/GLP-1 agonist.
Key Clinical Results
In a Phase 2 trial for people with obesity (without diabetes), retatrutide produced substantial weight loss after 48 weeks:
β’Up to 24.2% mean weight reduction at the 12 mg dose.
β’Weight loss continued without plateauing by the end of the study.4
It also showed benefits in reducing liver fat (in people with MASLD/MASH), improving glycemic control, blood pressure, and lipids. Phase 3 trials (TRIUMPH program) are ongoing or have reported strong results, with some data suggesting even higher average weight loss (around 28-30% in certain reports).23
Current Status (as of May 2026)
β’Not yet FDA approved or commercially available.
β’Only accessible through clinical trials.
β’It is administered as a subcutaneous injection once per week, with a half-life of about 6 days.3
Side Effects
Common side effects are similar to other GLP-1-based drugs (nausea, vomiting, diarrhea, constipation), often improving with dose escalation. The added glucagon agonism can cause increased heart rate in some people.18
Retatrutide represents a promising next-generation βGLP-3β style therapy, potentially offering greater efficacy than current options due to its multi-pathway approach targeting both appetite suppression and increased energy expenditure. More Phase 3 data is expected in 2026.
(Thanks to Grok)
Any Prime Minister worth the title should be able to survive three hours sitting across from Joe Rogan. I can easily see Kemi Badenoch doing that. Keir Starmer wouldn't last fifteen minutes.